 |
A
call for sponsorship to support the running and future development
of Glycosmedia |
| |
Click on the above headline for an overview
of the Glycosmedia diabetes news service and our call for sponsorship.
Brief details on how sponsorship will work can be seen here. For further details please contact (Jim Young, Editor-in-Chief) |
| |
|
|
Appropriate
advancement of type 2 diabetes therapy |
| |
An editorial workgroup meeting consisting of
a multidisciplinary panel of diabetes thought leaders recently
convened to provide additional insight on these issues. Their recommendations
and viewpoints are reported in this supplement (Current Clinical
Practice) |
| |
|
|
Oramed
Pharmaceuticals Launches Phase 1A Trials of its InsulinSuppository |
| |
An insulin suppository represents an important
development in the treatmentof diabetes as it provides a painless
alternative for effective insulin delivery (Oramed) |
| |
|
|
Novo
taps stem cells in hunt for diabetes cure |
| |
The world leader in diabetes care said on Thursday
it had launched a new collaboration to develop a treatment for
type 1 diabetes by programing stem cells to turn into insulin-producing
cells (Reuters) |
| |
|
|
Forest
Laboratories, Inc.and Phenomix Corporation in $340 Million Diabetes
Deal |
| |
Announcing that they have entered into a definitive
collaboration agreement to develop and commercialize dutogliptin
(BioSpace) |
| |
|
|
Hypoglycemia |
| |
This article is the 8th in a 12-part series
reviewing the fundamentals of diabetes care for physicians in training
(Clinical Diabetes) |
| |
|
|
Sources
of funding |
| |
If you know of any sources of funding that we
can contact to support the running and future development of Glycosmedia
then please mail Jim Young, Editor-in-Chief jim@glycosmedia.com |
| |
|
